Kathleen Pantaze, LCSW in Mesquite, NV - Social Worker

Kathleen Pantaze, LCSW is a Social Worker - Clinical based in Mesquite, Nevada. Kathleen Pantaze is licensed to practice in Nevada (license number 3013C) and her current practice location is 61 N Willow St, Ste 4, Mesquite, Nevada. She can be reached at her office (for appointments etc.) via phone at (702) 346-4696.

NPI number for Kathleen Pantaze is 1215068820 and her current mailing address is 4126 Technology Way, Suite 102, Carson City, Nevada. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1215068820.

Contact Information

	Kathleen Pantaze, LCSW
	61 N Willow St, Ste 4, Mesquite, NV 89027-4785
	(702) 346-4696
	(702) 346-4699

Healthcare Provider's Profile

Full Name	Kathleen Pantaze
Gender	Female
Speciality	Social Worker - Clinical
Location	61 N Willow St, Mesquite, Nevada
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1215068820
Provider Enumeration Date: 03/07/2007
Last Update Date: 07/09/2007

Medical Identifiers

Medical identifiers for Kathleen Pantaze such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1215068820	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
101YA0400X	Counselor - Addiction (substance Use Disorder)	845L (Nevada)	Primary
1041C0700X	Social Worker - Clinical	3013C (Nevada)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Kathleen Pantaze is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Kathleen Pantaze, LCSW 4126 Technology Way, Suite 102, Carson City, NV 89706-2009 Ph: (775) 687-7573	Kathleen Pantaze, LCSW 61 N Willow St, Ste 4, Mesquite, NV 89027-4785 Ph: (702) 346-4696

News Archive

Could peridomestic mammals act as zoonotic reservoirs for SARS-CoV-2?

In new research from researchers in the USA and Australia peridomestic mammals, which live in and around human habitations, have been investigated to ascertain how SARS-CoV-2 can affect species external to, but in close proximity to, the human population.

Research findings could provide breakthrough for development of effective therapies for NSCLC

Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.

Researchers show how errant form of LYP can disrupt the immune system

Autoimmune diseases, such as Type I diabetes and rheumatoid arthritis, are caused by an immune system gone haywire, where the body's defense system assaults and destroys healthy tissues. A mutant form of a protein called LYP has been implicated in multiple autoimmune diseases, but the precise molecular pathway involved has been unknown.

New study examines effect of exercise on outcomes for older breast cancer survivors

Physician-scientists at University Hospitals Case Medical Center's Seidman Cancer Center and Case Western Reserve University School of Medicine are leading a new study exploring the impact of exercise on outcomes for older breast cancer survivors.

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

KaloBios Pharmaceuticals, Inc. today announced an agreement with Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, for the development and commercialization of KB001, an investigational new biologic for the treatment or prevention of Pseudomonas aeruginosa (Pa) infections. Sanofi Pasteur will be responsible for the development and commercialization of KB001 and initially focus on hospital indications, including the prevention of Pa pneumonias in mechanically ventilated patients.

Kathleen Pantaze, LCSW - Counselor in Mesquite, NV